文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

多中心INTELLIGENCE试验中白细胞血液生物标志物与拉曼分析:重症监护室(INTELLIGENCE-1)与急诊科(INTELLIGENCE-2)

Blood Biomarker and Raman Analysis of Leukocytes in the Multicenter Intelligence Trials: At the Intensive Care Unit (Intelligence-1) and the Emergency Department (Intelligence-2).
PubMed 文献 · Shock · 2025-09-25
一句话结论在六中心279例患者中,白细胞拉曼评分对脓毒症临床鉴别未提供超越传统生物标志物的附加价值。

脓毒症缺乏理想筛查工具,既往单中心试验提示基于白细胞拉曼光谱的新型生物光子标志物有助于分层识别感染与脓毒症。INTELLIGENCE研究在两国六中心分析279例患者,每例1小时内测量约1500个白细胞拉曼光谱。结果显示,白细胞拉曼评分鉴别能力与C反应蛋白、降钙素原、白细胞介素-6、可溶性尿激酶型纤溶酶原激活物受体等单个传统生物标志物相当,但在INTELLIGENCE-1重症感染患者队列中未能提供附加的临床鉴别价值;将分类模型从INTELLIGENCE-1迁移至双盲INTELLIGENCE-2急诊科异质患者队列后,拉曼评分同样未能提供附加价值。作者认为该技术理论上仍有前景,但需更多基础、转化与临床研究来完善其可用性和临床角色。

要点

  • INTELLIGENCE研究纳入两国六中心279例患者,每例在1小时内测量约1500个白细胞的拉曼光谱。
  • 白细胞拉曼评分的鉴别能力与C反应蛋白、降钙素原、白细胞介素-6、可溶性尿激酶型纤溶酶原激活物受体等单个传统生物标志物相当。
  • 在INTELLIGENCE-1重症监护感染患者队列中,拉曼评分未能为脓毒症临床鉴别提供附加价值。
  • 将分类模型从INTELLIGENCE-1迁移至双盲INTELLIGENCE-2急诊科异质患者队列后,拉曼评分同样未能提供附加价值。
  • 作者认为白细胞拉曼评估理论上仍可能是脓毒症诊断与患者分层的有前景工具,但需更多基础、转化与临床研究来完善其可用性和临床角色。

适用人群与场景

  • INTELLIGENCE-1:重症监护室中感染患者队列。
  • INTELLIGENCE-2:双盲试验中急诊科招募的异质患者队列。
  • 两研究合计279例患者,来自两国六中心。

研究设计与关键结果

  • 研究类型:多中心临床研究(INTELLIGENCE-1与INTELLIGENCE-2),两研究合计279例患者,来自两国六中心。
  • 每例患者测量约1500个白细胞的拉曼光谱,测量在仅1小时内完成。
  • 白细胞拉曼评分的鉴别能力与单个传统生物标志物(C反应蛋白、降钙素原、白细胞介素-6、可溶性尿激酶型纤溶酶原激活物受体)相当。
  • 在INTELLIGENCE-1重症监护感染患者队列中,拉曼评分未能为脓毒症临床鉴别提供附加价值。
  • 将分类模型从INTELLIGENCE-1迁移至双盲INTELLIGENCE-2急诊科异质患者队列后,拉曼评分未能提供附加价值。

证据类型、等级与局限

  • 证据类型:多中心临床研究(INTELLIGENCE-1与INTELLIGENCE-2)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。
  • 作者认为,白细胞拉曼评估理论上仍可能是脓毒症诊断与患者分层的有前景工具,但需更多基础、转化与临床研究来完善其可用性和临床角色,可能还需考虑将失调宿主反应的病理生理学问题纳入表型分层。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, goes along with a complex and not yet fully understood host response. Despite many different biomarkers, optimal screening tools to identify patients with sepsis are still needed. In a previous, single-center clinical trial with well-defined and well-separated patient cohorts, a new biophotonic marker based on the Raman spectroscopic characterization of leukocytes showed added value to stratify patients and identify infection and sepsis.

RESULTS: In the INTELLIGENCE studies, 279 patients from six centers in two countries were analyzed, and the Raman spectra of ~1500 leukocytes per patient were measured within only 1 hour. This marks a huge step from bench to bedside regarding usability and technology readiness level of Raman spectroscopy in multicentre clinical trials. With a discriminatory power comparable to individual conventional biomarkers (C-reactive protein, procalcitonin, interleukin-6, and soluble urokinase-type plasminogen activator receptor), the Raman score of leukocytes could not provide added value to the clinical discrimination of sepsis in the INTELLIGENCE-1 study cohorts of intensive care patients with infections. When translating the classification model from INTELLIGENCE-1 to the heterogeneous patient cohort recruited at the emergency department of the double-blinded INTELLIGENCE-2 trial, the Raman score failed to provide added value.

CONCLUSIONS: In theory, Raman assessment of leukocytes might still be a promising tool for sepsis diagnosis and patient stratification, but there is more basic, translational, and clinical research needed to refine its usability and clinical role, probably also taking questions of the pathophysiology of the dysregulated host response for a phenotype stratification into account.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Giamarellos-Bourboulis EJ, Thomas-Rüddel D, Pistiki A, et al. Blood Biomarker and Raman Analysis of Leukocytes in the Multicenter Intelligence Trials: At the Intensive Care Unit (Intelligence-1) and the Emergency Department (Intelligence-2). Shock. 2025. PMID: 40997262. doi:10.1097/SHK.0000000000002699

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。